We are developing the next generation of biomarker test technology for healthcare providers and people living with diabetes and other metabolic conditions.  Our novel magnetic resonance system, myScanLabTM, is custom-designed for testing metabolite biomarkers such as glucose and cholesterol from a simple finger scan. Unlike a finger prick test meter or continuous glucose monitor (CGM) our device tests without breaking the skin and requires no disposable test strips or sensors.  Our solution will advance testing at point-of-care organizations such as primary care practices and senior living facilities by lowering recurring costs and improving patient outcomes.

Our MRS testing method enables non-invasive tests of glucose and other metabolites by scanning a finger. U.S. Patent No. 11,237,237.

Novel spectrometer and probe designs achieve extremely low noise for optimal measurement sensitivity yielding fast and accurate tests for point-of-care medicine.

Our proprietary RF excitation pulse sequence and DFT based resonance signal processing specific to glucose represents a major advance for accurate MRS testing.

Patent pending gradient shimming technology achieves excellent magnetic field uniformity and spectral resolution for biomarker test specificity.

Our patent pending magnet array design improves field strength to volume/weight relative to traditional Halbach arrays enabling a portable and more ergonomic form factor.

Spatially uniform high power circularly polarized RF excitation and high sensitivity I/Q signal reception with a probe designed for in vivo measurements.

We are developing a portable, accurate, and convenient to use device for testing biomarkers used in the screening, diagnosis, and management of metabolic conditions like diabetes.  For many people with or at risk for diabetes the required glucose test frequency is too high to be acceptable with finger prick testing but not high enough to justify a continuous glucose monitor (CGM).  Using our non-invasive devices to conduct more frequent spot-testing for screening and optimal condition management enables lifestyle interventions shown to prevent diabetes in 6 of 10 people with pre-diabetes.

We believe the metabolome is the next frontier for precision medicine.  As the complete ensemble of small molecule metabolites, both endogenous and exogenous, the human metabolome reflects interaction of an individual's genome with their environment.  It is where the rubber meets the road.  There is a metabolic basis for most disease processes and an urgent need to provide better insight through high quality testing.  For example over 50% of the 463 million people living with diabetes around the world are undiagnosed. Point-of-care testing needs an accurate, portable, non-invasive technology for detection and quantitation of small molecule metabolites.